MedTrace Logo

Transfer of Energy Capacitive and Resistive Therapy on Shoulder Range of Motion In Idiopathic Adhesive Capsulitis

NCT07788287 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-08-26

No results posted yet for this study

Summary

The current study's general aim is to compare the effectiveness of Transfer of Energy Capacitive and Resistive (TECAR) therapy combined with stretching versus stretching alone in patients with adhesive capsulitis stage 2,3 on range of motion, pain, and function.

Conditions

  • Adhesive Capsulitis

Interventions

DEVICE

Transfer of Energy Capacitive and Resistive (TECAR) Therapy

To apply TECAR therapy, the patient will lie supine, with the passive electrode, a flexible rectangular stainless steel plate measuring 150 £ 200 mm, placed under the affected side's scapula. A rigid circular metallic electrode with a 60-mm diameter will be used as the active electrode. Using the resistive mode with the power of 8 to 10 mA, the active electrode will be circularly moved continuously for 10 minutes on the anterior-inferior shoulder capsule while the patient's arm will be held at the end existing range of abduction and external rotation. As well, a conductive cream will be used as a coupling medium between the electrodes and the skin. Based on the manufacturer's recommendation for safe performance, the TECAR intensity will be set as the most effective method, causing no pain based on each patient's feedback.

OTHER

Stretching exercises

While the patients were lying on the bed, they would receive cyclic (intermittent) stretching. Cyclic stretching is the application, release, and reapplication of a relatively short-duration stretch force repeatedly but progressively. Twenty seconds of stretching and 10 seconds of rest will be used 10 times in each of the following directions (flexion, scapular plane abduction, external rotation, and internal rotation) and stretch to target rotator cuff interval.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Mohamed A Mohamed, As.professor · Cairo University

  • Mona M Ibrahim, As.Professor · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2027-03-15
Completion
2027-03-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07788287 on ClinicalTrials.gov